´Ý±â
TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.
Home > Learning center > Stem Cell > ´Ù¾çÇÑ ½ÇÇè Àû¿ë »ç·Ê > [Àû¿ë³í¹®] iPSC·ÎºÎÅÍ °£¼¼Æ÷ ºÐÈ­½Ã½ºÅÛ

[Àû¿ë³í¹®] iPSC·ÎºÎÅÍ °£¼¼Æ÷ ºÐÈ­½Ã½ºÅÛ

-

[Àû¿ë³í¹®] iPSC·ÎºÎÅÍ °£¼¼Æ÷ ºÐÈ­½Ã½ºÅÛ

Cellartis iPS Cell to Hepatocyte Differentiation System Àû¿ë ³í¹®

Àû¿ë Á¦Ç°

Àû¿ë ³í¹®

Cellartis¢ç iPS Cell to Hepatocyte Differentiation System (Code Y30055)

Prunellae Spica Extract Suppresses Teratoma Formation of Pluripotent Stem Cells through p53-Mediated Apoptosis


https://doi.org/10.3390/nu12030721
Prunellae Spica Extract Suppresses Teratoma Formation of Pluripotent Stem Cells through p53-Mediated Apoptosis
Aeyung Kim, Seo-Young Lee, Chang-Seob Seo, Sun-Ku Chung

¾Æ·¡ ³»¿ëÀº ´ÙÄ«¶óÄÚ¸®¾Æ¿¡¼­ Á÷Á¢ ¹ø¿ªÇÑ ³»¿ëÀ¸·Î, Çؼ®ÇÏ´Â °úÁ¤¿¡¼­ ¿øÀÛÀÚÀÇ Àǵµ¿Í »óÀÌÇÑ ³»¿ëÀÌ Æ÷ÇԵǾî ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. Çмú Á¤º¸¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â °æ¿ì ¿ø¹®À» Âü°íÇÏ¿© Áֽñ⸦ ¹Ù¶ø´Ï´Ù.

¡á Abstract ¹Ì¸®º¸±â
Induced pluripotent stem cells (iPSCs)´Â ¹«ÇÑÇÑ self-renewal°ú ºÐÈ­ ´É·Â µî ¹è¾ÆÁٱ⼼Æ÷¿Í À¯»çÇÑ Æ¯¼ºÀ» º¸ÀδÙ. In-vitro »ó¿¡¼­ ºÐÈ­µÈ iPSCs´Â undifferentiated iPSCs (USCs)°¡ ¼¼Æ÷Ä¡·áÁ¦ ³»¿¡ Á¸ÀçÇÒ ¼ö ÀÖ°í, in-vivo·Î ÀÌ½Ä ÈÄ teratomaÀ» Çü¼ºÇÒ ¼ö ÀÖ´Ù. µû¶ó¼­ ³²¾ÆÀÖ´Â USC¸¦ ¼±ÅÃÀûÀ¸·Î Á¦°ÅÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÏ´Ù. Prunellae Spica (PS)´Â ÀüÅë ¾à¿ë½Ä¹°·Î, Ç×¾Ï, Ç×»êÈ­Á¦, Ç׿° ÀÛ¿ëÀ» ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÁö¸¸, iPSC¿¡¼­ÀÇ ÀÛ¿ëÀº ¿¬±¸µÈ ¹Ù ¾ø¾ú´Ù. º» ¿¬±¸¿¡¼­´Â ¿¡Åº¿Ã·Î ÃßÃâÇÑ PS (Extract of PS, EPS)°¡ G2/M ¼¼Æ÷ ÁÖ±â Á¤Áö, ¼¼Æ÷ ³» È°¼º »ê¼Ò »ý¼º, ¹ÌÅäÄܵ帮¾Æ ¸· ÀüÀ§ º¯°æ ¹× USCÀÇ caspase È°¼ºÈ­¸¦ ÅëÇØ USCÀÇ ¼¼Æ÷ »ç¸ê (apoptotic ell death)À» È¿°úÀûÀ¸·Î À¯µµÇÑ´Ù´Â °ÍÀ» È®ÀÎÇÏ¿´´Ù. ¶ÇÇÑ, EPS´Â p53 ÃàÀû°ú downstream À¯ÀüÀÚ ¹ßÇöÀ» Áõ°¡½ÃÄ×À¸³ª, p53 knockout (KO) USC¿¡¼­´Â EPS°¡ ¼¼Æ÷ »ç¸êÀ» À¯µµÇÏÁö ¾Ê¾ÒÀ¸¸ç, À̷νá EPS·Î ÀÎÇÑ USC »ç¸êÀº p53-dependentÇÔÀ» È®ÀÎÇÏ¿´´Ù. °Ô´Ù°¡, iPSCs À¯·¡ ºÐÈ­ ¼¼Æ÷¿¡¼­ EPS´Â À¯Àü µ¶¼ºÀ» À¯¹ßÇÏÁö ¾Ê¾Ò´Ù. Injection Àü EPS¸¦ ó¸®ÇßÀ» ¶§, p53 WTÀÇ iPSC¿¡¼­´Â ovo teratoma Çü¼ºÀ» È¿°úÀûÀ¸·Î ¹æÁöÇÏ¿´À¸³ª, p53 KO iPSC¿¡¼­´Â ¹æÁöÇÏÁö ¸øÇß´Ù. À̸¦ Á¾ÇÕÇßÀ» ¶§, º» ¿¬±¸ °á°ú´Â EPS´Â teratoma Çü¼ºÀ» °­ÇÏ°Ô ¾ïÁ¦ÇÏ´Â È°¼ºÀ» °¡Áö°í, ºÐÈ­µÈ ¼¼Æ÷¿¡¼­´Â À¯Àü µ¶¼ºÀ» ³ªÅ¸³»Áö ¾Ê¾ÒÀ¸¹Ç·Î, ¾ÈÀüÇÏ°í È¿À²ÀûÀÎ iPSC ±â¹ÝÀÇ ¼¼Æ÷ Ä¡·áÁ¦ °³¹ß¿¡ È°¿ëµÉ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀδÙ.

¡á Takara Á¦Ç°À» ÀÌ¿ëÇÑ method ¹Ì¸®º¸±â
p53 WT hiPSC, p53 KO hiPSC¸¦ definitive endoderm (DE)À» °ÅÃÄ hepatocyte·Î ºÐÈ­ À¯µµÇÏ¿© ½ÇÇèÀ» ÁøÇàÇÏ¿´´Ù. °¢ hiPSC´Â Cellartis¢ç DE Differentiation Kit with DEF-CS Culture System (Code Y30035)¸¦ ÀÌ¿ëÇØ definitive endodermÀ¸·Î ºÐÈ­ÇÏ¿´´Ù. DE·Î ºÐÈ­¸¦ À¯µµÇϱâ Àü, °¢ hiPSC´Â Cellartis¢ç DEF-CS Culture SystemÀ» ÀÌ¿ëÇØ 5 Â÷·ÊÀÇ °è´ë·Î È®´ë ¹è¾çÇÏ¿´´Ù. DE·ÎÀÇ ºÐÈ­ 7ÀÏÂ÷¿¡ °¢ ¼¼Æ÷¸¦ TrypLE¢â Select È¿¼Ò·Î detachÇÑ ÈÄ, Cellartis¢ç iPS Cell to Hepatocyte Differentiation System (Code Y30055)¸¦ ÀÌ¿ëÇØ hepatocyte·Î ºÐÈ­ À¯µµÇÏ¿´´Ù. ºÐÈ­ 9, 11ÀÏÂ÷¿¡´Â hepatocyte progenitor mediumÀ¸·Î ¹èÁö¸¦ ±³Ã¼ÇÏ¿´À¸¸ç, ºÐÈ­ 14, 16ÀÏÂ÷¿¡´Â hepatocyte maturation mediumÀ¸·Î ¹èÁö¸¦ ±³Ã¼ÇÏ¿´´Ù. ºÐÈ­ 18ÀÏÂ÷ºÎÅÍ´Â 2Àϸ¶´Ù hepatocyte maintenance mediumÀ¸·Î ¹èÁö¸¦ ±³Ã¼ÇÏ¿´´Ù. ºÐÈ­µÈ ¼¼Æ÷´Â hepatocyte markerÀÎ CYP34A, alpha-fetoprotein (AFP), albumin ¹ßÇöÀÌ Áõ°¡ÇÏ¿´°í, Oct4 ¹ßÇöÀÌ °¨¼ÒÇÏ¿´´Ù.

¡á ³í¹®¿¡¼­ »ç¿ëµÈ Takara °ü·Ã Á¦Ç° ¾Ë¾Æº¸±â
Cellartis¢ç iPS Cell to Hepatocyte Differentiation System (Code Y30055)
  • hiPSCÀÇ definitive endoderm (DE) ºÐÈ­ ÈÄ, DEÀÇ hepatocyte ºÐÈ­ À¯µµÇÏ´Â Àü °úÁ¤ Áö¿ø
  • 25°³ hiPS ¼¼Æ÷ÁÖ¿¡¼­ Àû¿ë¼ºÀÌ È®ÀεǾúÀ¸¸ç, ÇϳªÀÇ ÇÁ·ÎÅäÄÝ·Î ´Ù¾çÇÑ hiPS ¼¼Æ÷ÁÖ¿¡ Àû¿ë °¡´É
  • 90% ÀÌ»óÀÇ È¿À²·Î ±â´ÉÀûÀÎ °£¼¼Æ÷ ºÐÈ­ ¹× Àå±â ¹è¾ç (ºÐÈ­ ÈÄ 14ÀÏ ÀÌ»ó) °¡´É
  • È°¿ë ¿¹: ´Ù¾çÇÑ À¯ÀüÀû Á¤º¸¸¦ °¡Áö´Â Áúº´ ¸ðµ¨ ¿¬±¸, ƯÁ¤ Áúȯ/ȯÀÚ¸¦ À§ÇÑ ¸ÂÃã ÀÇÇÐ »ó¿ëÈ­